Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported a more than 300% increase in committed customer orders for its contract development and manufacturing organization (CDMO) business, alongside approximately $5.3 million in net proceeds from recent equity financings, according to a shareholder letter from CEO Amir Reichman. The disclosure, detailed in a press release, underscores the company’s efforts to strengthen its financial position and expand its service offerings.
As of Oct. 20, 2026, Scinai reported approximately $8.1 million in committed customer orders, up from $1.9 million at year-end 2025. The growth was driven in part by a new agreement with a U.S.-based biopharmaceutical company that includes approximately $5.1 million in committed base service fees. That agreement also contemplates approximately $5.85 million in additional, uncommitted services, bringing the combined potential opportunity to more than $10 million, subject to further agreements and project milestones.
The financing, which includes a standby equity purchase agreement drawdown and a private placement with warrant exercises, is expected to support operations through late 2027, and potentially into the third quarter of 2028 if additional project phases are activated and delivered. Management estimates that current cash resources and expected customer payments will provide the extended runway.
The news matters because it signals growing demand for Scinai’s CDMO services and improved liquidity, which could reduce the company’s reliance on external funding for its immunotherapy pipeline. Scinai remains focused on expanding its CDMO customer base, improving facility utilization, and pursuing capital-efficient development of its NanoAb immunotherapy platform through grants and partnerships. The company’s CDMO arm, Scinai Biopharma Services Ltd., provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.
For investors, the update offers a clearer view of Scinai’s revenue visibility and financial stability. The committed orders and financing extend the company’s operating horizon, potentially allowing it to advance its pipeline while growing its service business. The full press release is available via https://ibn.fm/3C1F4, and the latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides access to wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
